Miami, FL
Ketamine Therapy clinics in Miami
Ketamine therapy in Miami is delivered through psychiatry-led clinics, anesthesia-run infusion centers, and ketamine-assisted psychotherapy practices, with hospital referrals often tied to Jackson Health System, Baptist Health, and University of Miami Health. Demand reflects a large international, Latin American, and aesthetic-focused patient base and an active local market for treatment-resistant depression, PTSD, and chronic pain.
The strongest evidence supports intranasal esketamine (Spravato, FDA-approved for treatment-resistant depression) and intravenous racemic ketamine (off-label, substantial supporting evidence). Clinics in Miami, Florida also offer intramuscular, sublingual, and at-home oral lozenge protocols, with weaker evidence and variable safety oversight. Florida Department of Health oversight of office-based surgery and stem cell claims shapes which clinics can operate as cash-pay versus insurance-eligible.
With ketamine clinics on Regenerated.com in Miami, patients can compare whether the clinic offers psychiatric evaluation, anesthesia monitoring during infusion, and structured preparation and integration.
Ketamine Expert Clinic
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- Ozone Therapy
- IV Therapy
MIAMI MENTAL HEALTH & WELLNESS
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Hormone Replacement Therapy (HRT)
Infinity Medical Wellness
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- IV Therapy
- Ketamine Therapy
Hidalgo TMS Psychiatric Services
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
Regulatory context
A note on Florida's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Florida Comprehensive Drug Abuse Prevention and Control Act
Mirrors federal scheduling; psilocybin, MDMA, and ibogaine remain Schedule I. -
Florida Office-Based Anesthesia Rule (64B8-9.009)
Applies to office-based procedures including ketamine infusions above moderate sedation thresholds, requiring specific registration and protocols.
Florida enforces federal scheduling. The Florida Board of Medicine and Board of Osteopathic Medicine oversee prescriber conduct, with heightened scrutiny on office-based anesthesia and controlled substance prescribing since the state's pain clinic crackdowns. DEA enforcement targets ketamine diversion and compounding. Florida's E-FORCSE PDMP requires controlled substance reporting. Ryan Haight Act applies to telehealth ketamine prescriptions.